Back to search

National and Kapodistrian University of Athens

Διερεύνηση της εμπλοκής της σουρβιβίνης στις ιδιοπαθείς φλεγμονώδεις νόσους του εντέρου

Abstract

dc:description

AIM: To genotype the survivin promoter polymorphisms namely -31G/C, -241T/C, and -625G/C, in patients with either Crohn’s disease (CD) or ulcerative colitis (UC) and in controls, and to identify a possible association between individual genetic variation, disease susceptibility and response to infliximab.METHODS: The expression of survivin in intestinal tissue and blood of patients and controls was detected by semiquantitativereverse transcription-polymerase chainreaction (RT-PCR). A total of 97 CD, 88 UC, and 152 healthy controls were evaluated for the three polymorphisms in survivin promoter. Polymorphisms were identified using the PCR–RFLP technique.Infliximab at a dose of 5 mg/kg was administered intravenously at weeks 0, 2, 6 and then every 8 wk. Clinical and serological responses were assessed, the endoscopic response was evaluated by ileocolonoscopy performed at baseline and after 12-20 wk of therapy and the CD patients were classified as responders and non-responders.RESULTS: No significant differences were found between mRNA levels of survivin between CD, UC patients and controls in both tissue and blood samples. The significant differences in both allele and genotype frequencies between CD, UC patients and controls were found in -31C/G polymorphism. For this SNP, the frequencies of the C alleles were 0.56 in CD, 0.63 in UC, and 0.48 in the controls, thus the -31C allele had a 1.46-fold increased risk of CD with statistical significance (95%CI 1.02–2.10), and a 1.95-fold increased risk of UC with statistical significance (95%CI 1.33–2.85). Our results indicate that the -625G/C and -241T/C polymorphisms were not associated with the development of CD or UC, however, these polymorphisms were found to be significantly over-represented in controls. The polymorphisms tested were not significantly associated with clinicopathological characteristics among CD and UC patients. Additionally, no significant association was found between -31C/G polymorphism and the clinical response of CD patients to infliximab.Conclusion: Survivin promoter polymorphism -31C/G might influence the susceptibility to CD and UC in the Greek population, but not the CD patients response to anti-TNF drugs.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Rapti, Emmanouela
  • Ράπτη, Εμμανουέλα

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41441

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Rapti, Emmanouela; Ράπτη, Εμμανουέλα. Διερεύνηση της εμπλοκής της σουρβιβίνης στις ιδιοπαθείς φλεγμονώδεις νόσους του εντέρου. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/41441